Table 1.

Participant characteristics at time of random assignment for women with an intact uterus at entry in the NSABP STAR/P-2 trial

Participant Characteristic	Tamoxifen (n = 4739)		Raloxifene (n = 4717)
	No.	%	No.	%	P
Age (years)
≤ 49	237	5.0	233	4.9	0.99
50–59	2592	54.7	2584	54.8
60–69	1516	32.0	1515	32.1
≥ 70	394	8.3	385	8.2
Mean (SD)	58.8 (6.8)		58.8 (6.8)
Parity
≤ 1	1252	26.4	1211	25.7	0.41
≥ 2	3487	73.6	3506	74.3
History of oral contraceptive use
No	1501	31.7	1540	32.6	0.31
Yes	3238	68.3	3177	67.4
History of estrogen therapy
No	1763	37.2	1823	38.6	0.15
Yes	2976	62.8	2894	61.4
No. of relatives with breast cancer
0	1489	31.4	1446	30.7	0.22
1	2399	50.6	2404	51.0
2	710	15.0	752	15.9
3 or more	141	3.0	115	2.4
History of diabetes
Yes	241	5.1	227	4.8	0.54
No	4498	94.9	4490	95.2
History of hypertension
Yes	1417	29.9	1383	29.3	0.54
No	3322	70.1	3334	70.7
Smoking status
Never	2414	50.9	2448	51.9	0.29
Former	1860	39.2	1780	37.7
Current	443	9.3	458	9.7
Unknown	22	0.5	31	0.7
BMI*
<25.0	1619	34.2	1576	33.4	0.74
25.0 – 29.9	1638	34.6	1646	34.9
≥ 30.0	1481	31.3	1494	31.7
Mean (SD)	28.1(6.0)		28.2 (6.1)

^*BMI was unavailable for one person in the tamoxifen group and one person in the raloxifene group.